Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.7.0.1
Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Net sales $ 144,037 $ 130,973 $ 406,425 $ 364,261
Operating income 32,305 43,527 73,892 110,581
Costs recognized on sale of acquired inventory (3,136) (1,082) (11,205) (3,439)
Amortization of acquisition related intangible assets     (33,504)  
Acquisition related expenses (2,691) (1,313) (17,792) (2,284)
Stock based compensation (3,974) (2,317) (11,219) (6,676)
Corporate general, selling, and administrative (48,107) (35,217) (150,025) (102,842)
Acquisition Related [Member]        
Amortization of acquisition related intangible assets (11,689) (7,276) (33,504) (22,048)
Operating Segments [Member]        
Operating income 54,502 56,179 150,611 147,848
Intersegment Eliminations [Member]        
Net sales (43) (35) (80) (63)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative (707) (664) (2,999) (2,820)
Biotechnology [Member] | Operating Segments [Member]        
Net sales 94,516 81,386 267,256 232,984
Operating income 45,242 45,133 127,195 124,436
Diagnostics [Member] | Operating Segments [Member]        
Net sales 25,978 29,929 74,542 76,013
Operating income 6,004 9,454 18,108 21,464
Protein Platforms [Member] | Operating Segments [Member]        
Net sales 23,586 19,693 64,707 55,327
Operating income $ 3,256 $ 1,592 $ 5,308 $ 1,948